VECIMA-NETWORKS
8.5.2024 13:31:34 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) today announced it has signed an agreement with AXING AG, a provider of telecommunications products and services in Germany, to serve as a reseller of Vecima’s industry-leading Entra® Distributed Access Architecture (DAA) product portfolio, including the Entra SC-1D Remote MACPHY Device and the Entra EN2112 Remote PHY Access Node.
Vecima's Entra SC-1D Remote MACPHY Device, a cornerstone of the Entra DAA family, is specifically designed for DAA applications, enabling operators to transition their networks toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving the MAC and PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability.
The Entra EN2112 Remote PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS (virtual cable modem termination systems), creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber coax (HFC) network capacity and deliver increased bandwidth to subscribers.
"The AXING Group has a long track record of delivering industry-leading solutions to cable network operators,” said Johannes Moser, CEO of AXING. “With DEV Systemtechnik, we have enabled cable operators to upgrade their networks with advanced CCAP/Remote MACPHY systems since the beginning of 2019. The partnership with Vecima will significantly enhance our offering with state-of-the-art broadband HFC access systems, and our customers will benefit from globally-leading products and excellent support.”
‟Vecima continues to deliver powerful DAA solutions to operators around the world, and we are excited to work with AXING to transform broadband experiences throughout Germany,” said Ryan Nicometo, Senior Vice President and General Manager, Vecima Video & Broadband Solutions. “We look forward to highlighting our innovative cable and fiber access solutions that deliver ground-breaking speed and capacity at ANGA COM 2024 in May.”
The Vecima Distributed Access Architecture (DAA) product portfolio, recognized by the Dell’Oro Group for the third consecutive year as the North America market share leader in Remote MACPHY (R-MACPHY) and 10G-EPON Remote Optical Line Terminal (R-OLT) solutions, is deployed by operators around the world. With full support for all next-generation cable access technologies, high-value legacy services, and proven interoperability, the networks of tomorrow are deployable today. For more information about Vecima’s Entra DAA platform, visit vecima.com/network-access/interoperable-daa-solutions.
Visit Vecima Networks at ANGA COM 2024
May 14-16 in Cologne, Germany
Koelnmesse Hall 8, Stand A20
About AXING AG
AXING is a Swiss-based company that specializes in manufacturing high-tech solutions for TV and multimedia reception and distribution technology. We partner with cable network providers, city carriers, broadcasters, the housing industry, and the hospitality sector to offer innovative and future-proof solutions, along with excellent and reliable service. Our R&D department is equipped with all necessary measuring and testing equipment to ensure quality assurance. We adhere to AXING's corporate philosophy of providing our customers with maximum precision and quality, and we carry out our activities with Swiss thoroughness.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508933251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom